Zerlasiran may prevent heart disease by lowering lipoprotein(a) concentrations: JAMA
A new study revealed that Zerlasiran is not just safe and tolerable but also effective in substantially reducing the levels of lipoprotein(a) [Lp(a)] which is a key factor in the development of atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis. The key findings of this study were published in the Journal of American Medical Association. […]